● Live


You are here

Sun Pharma rises as its arm plan to acquire Thallion Pharmaceuticals

  • Mar-20-2017
  • 14 Hrs IST

Sun Pharmaceutical Industries is currently trading at Rs. 708.55, up by 1.85 points or 0.26% from its previous closing of Rs. 706.70 on the BSE.

The scrip opened at Rs. 708.00 and has touched a high and low of Rs. 711.50 and Rs. 705.25 respectively. So far 78525 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 854.50 on 05-Aug-2016 and a 52 week low of Rs. 572.40 on 09-Nov-2016.

Last one week high and low of the scrip stood at Rs. 728.45 and Rs. 678.10 respectively. The current market cap of the company is Rs. 169977.78 crore.

The promoters holding in the company stood at 54.39%, while Institutions and Non-Institutions held 33.97% and 11.65% respectively.

Taro Pharmaceuticals (Canada), an indirect subsidiary of Sun Pharmaceutical Industries, has entered into an agreement to acquire all of the issued and outstanding shares of Thallion Pharmaceuticals, a Canadian pharmaceutical corporation. Post the acquisition of Thallion Pharmaceutical, Taro Pharmaceuticals would have only rights for development of orphan drug candidate, Shigamab, which targets E. Coli-induced hemolytic-uremic syndrome.

Sun Pharmaceutical Industries is an Indian multinational pharmaceutical company that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) primarily in India and the United States.